BLNP 003Alternative Names: BLNP-003
Latest Information Update: 03 Sep 2015
At a glance
- Originator BL-&-H
- Class Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
Most Recent Events
- 03 Sep 2015 Clinical trials in Cryopyrin associated Periodic Syndromes in South Korea (unspecified route) before September 2015
- 03 Sep 2015 Clinical trials in Rheumatoid arthritis in South Korea (unspecified route) before September 2015